Overcoming Challenges Facing Rural Hospitals: I Don’t Care with Kevin Stevenson

 

On this episode of I Don’t Care, host Kevin Stevenson is joined by Eastland Memorial Hospital’s Ron Hunt, who brings to the table a lengthy career of experience in rehab and post-acute care, to discuss the ins and outs of rural healthcare.Listen to I Don’t Care LIVE every Friday morning at 9:30AM CST to stay up to date with everything going on in the healthcare industry.

Rural facilities can differ from those in larger metropolitan areas in a variety of ways, including the very nature of their staffs of medical professionals – rural facilities sometimes have to rely on episodic doctors willing to travel and work on location.
“We’re pretty fortunate here (at Eastland),” Hunt said. “We’ve got, I believe, five physicians that are still in town. … We’ve got a general surgeon, which you don’t see happen very much, anymore.”

Still, Hunt and Eastland also contract with an outside company through a hospitalist program, which allows for outside physicians to come into the hospital and stay with patients from the time they are admitted until discharge. Eastland’s ER operates in a similar manner.

Hunt and Stevenson also discussed the challenges that Eastland and rural facilities face, including aging populations, challenges in treating patients who are unemployed, and more
“There are a number of things that are going on in rural America that make it difficult for us to maintain the hospital,” Hunt said. “We have an older population. … The other thing that we see out here is we see a lot of people who are either unemployed or underemployed.”

Want more “I Don’t Care”? Catch up on all the episodes here!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More